SAR in the assessment of carcinogenesis: The MultiCASE approach

Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens

Volumn , Issue , 2003, Pages 175-206

  Rosenkranz, Herbert S ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018579809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203010822     Document Type: Chapter

References (98)

1. Richard, A.M. and Benigni, R., AI and SAR approaches for predicting chemical carcinogenicity: survey and status report, SAR QSAR Environ. Res., 13, 1-19, 2002.
2. Combes, R.D., The use of artificial intelligence systems for predicting toxicity, Pestic. Sci., 45, 179-194, 1995.
3. Rosenkranz, H.S., Cunningham, A.R., Zhang, Y.P., Claycamp, H.G., Macina, O.T., Sussman, N.B., Grant, S.G., and Klopman, G., Development, characterization and application of predictive-toxicology models, SAR QSAR Environ. Res., 10, 277-298, 1999.
4. Matthews, E. and Contrera, J., A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSARES software, Regul. Toxicol. Pharmacol., 28, 242-264, 1998.
5. Richard, A.M., Application of artificial intelligence and computer-based methods to predicting chemical toxicity, Knowledge Eng. Rev., 14, 307-317, 1999.
6. Helma, C., Gottmann, E., and Kramer, S., Knowledge discovery and data mining in toxicology, Stat. Meth. Med. Res. 9, 1-30, 2000.
7. Klopman, G. and Rosenkranz, H.S., Prediction of carcinogenicity/mutagenicity using MultiCASE, Mutat. Res., 305, 33-46, 1994.
8. Klopman, G. and Rosenkranz, H.S., Toxicity estimation by chemical substructure analysis: the Tox II program, Toxicol. Lett., 79, 145-155, 1995.
9. Sanderson, D.M. and Earnshaw, C.G., Computer prediction of possible toxic action from chemical structure: the DEREK system, Human Exp. Toxicol., 10, 261-273, 1991.
10. Ridings, J.E., Barratt, M.D., Cary, R., Earnshaw, C.G., Eggington, C.E., Ellis, M.K., Judson, P.N., Langowskin, J.J., Marchant, C.A., Payne, M.P., Watson, W.P., and Yih, T.D., Computer prediction of possible toxic action from chemical structure: an update of the DEREK system, Toxicology, 106, 267-279, 1996.
11. IARC, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Suppl. 6, International Agency for Research on Cancer, Lyon, France, 1988.
12. Balls, M., Blaauboer, B., Brusick, D., Frazier, J., Lamb, D., Pemberton, M., Reinhardt, C., Roberfroid, M., Rosenkranz, H., Schmid, B., Speilmann, H., Stammati, A.L., and Walum, E., Report and Recommendations of the CAAT/ERGATT Workshop on the Validation of Toxicity Test Procedures, Alternative to Laboratory Animals (ATLA), 18, 313-337, 1990.
13. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Pharmaceutical Drugs, Vol. 66, World Health Organization/International Agency for Research on Cancer, Lyon, France, 1996, 1-514.
14. Bartsch, H. and Malaveille, C., Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series, Cell Biol. Toxicol., 5, 115-127, 1989.
15. Shelby, M.D., The genetic toxicity of human carcinogens and its implications, Mutat. Res., 204, 3-15, 1988.
16. Ashby, J. and Morrod, R.S., Detection of human carcinogens, Nature, 352, 185-186, 1991.
17. Ennever, F.K., Noonan, T.J., and Rosenkranz, H.S., The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans, Mutagenesis, 2, 73-78, 1987.
18. Sontag, J.M., Page, N.P., and Saffiotti, V., Guidelines for Carcinogenicity Bioassay in Small Rodents, National Cancer Institute Carcinogenesis Technical Report Series No. 1, Publ. No. NIH76-801, Department of Health, Education and Welfare, Washington, D.C., 1976.
19. Chhabra, R.S., Huff, J.E., Schwetz, B.S., and Selkirk, J., An overview of prechronic and chronic toxicity/carcinogenicity experimental study design and criteria used by the National Toxicology Program, Environ. Health Persp., 86, 313-321, 1990.
20. Butterworth, B.E., Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential, Mutat. Res., 239, 117-132, 1990.
21. Cohen, S.M. and Ellwein, L.B., Cell proliferation in carcinogenesis, Science, 249, 1007-1011, 1990.
22. Preston-Martin, S., Pike, M.C., Ross, R.K., Jones, P.A., and Henderson, B.E., Increased cell division as a cause of human cancer, Cancer Res., 50, 7415-7421, 1990.
23. Cohen, S.M. and Ellwein, L.B., Genetic errors, cell proliferation and carcinogenesis, Cancer Res., 51, 6493-6505, 1991.
24. Ames, B.N. and Gold, L.S., Chemical carcinogenesis: too many rodent carcinogens, Proc. Natl. Acad. Sci. USA, 87, 7772-7776, 1990.
25. Ames, B.N. and Gold, L.S., Too many rodent carcinogens: mitogenesis increases mutagenesis, Science, 249, 970-971, 1990.
26. Liu, M., Sussman, N., Klopman, G., and Rosenkranz, H.S., Estimation of the optimal data base size for structure-activity analyses: the Salmonella mutagenicity data base, Mutat. Res., 358, 63-72, 1996.
27. Rosenkranz, H.S. and Cunningham, A.R., SAR modeling of unbalanced data sets, SAR QSAR Environ. Res., 12, 267-274, 2001.
28. Rosenkranz, H.S. and Cunningham, A.R., SAR modeling of genotoxic phenomena: the effect of supplementation with physiological chemicals, Mutat. Res., 476, 133-137, 2001.
29. National Academy of Sciences, Toxicity Testing. Strategies To Determine Needs and Priorities, National Academy Press, Washington, D.C., 1984.
30. Rosenkranz, H.S., Takihi, N., and Klopman, G., Structure-activity-based predictive toxicology: an efficient and economical method for generating non-congeneric data bases, Mutagenesis, 6, 391-394, 1991.
31. Takihi, N., Zhang, Y.P., Klopman, G., and Rosenkranz, H.S., An approach for evaluating and increasing the informational content of mutagenicity and clastogenicity databases, Mutagenesis, 8, 257-264, 1993.
32. Takihi, N., Zhang, Y.P., Klopman, G., and Rosenkranz, H.S., Development of a method to assess the informational content of structure-activity data bases, Quality Assurance: Good Practice, Regul., Law, 2, 255-264, 1993.
33. Zhang, Y.P., Sussman, N., Klopman, G., and Rosenkranz, H.S., Development of methods to ascertain the predictivity and consistency of SAR models: application to the U.S. National Toxicology Program rodent carcinogenicity bioassays, Quant. Struct.-Act. Rel., 16, 290-295, 1997.
34. Gold, L.S., Slone, T.H., and Ames, B.N., Overview and update of analyses of the carcinogenic potency database, in Handbook of Carcinogenic Potency and Genotoxicity Databases, L.S. Gold and E. Zeiger, Eds., CRC Press, Boca Raton, FL, 1997, 661-685.
35. Peto, R., Pike, M.C., Bernstein, L., Gold, L.S., and Ames, B.N., The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments, Environ. Health Perspect., 58, 1-8, 1984.
36. Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., deVeciana, M., Levinson, R., Hooper, N.K., Havender, W.R., Bernstein, L., Peto, R., Pike, M.C., and Ames, B.N., A carcinogenic potency database of the standardized results of animal bioassays, Environ. Health Perspect., 58, 9-319, 1984.
37. Purchase, I.F.H., Activity of 42 compounds in animal carcinogenicity studies, in Evaluation of Short-Term Tests for Carcinogens, E.F.J. DeSerres and J. Ashby, Eds., Elsevier, Amsterdam, 1981, 21-32.
38. Combes, R.D. and Haveland-Smith, R.B., Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowers Memorial Lecture, Mutat. Res., 98, 101-248, 1982.
39. Hueper, W.D. and Conway, W.D., Chemical Carcinogenesis and Cancers, Charles C Thomas, Springfield, IL, 1964, 294-318.
40. Ariens, E.J., Domestication of chemistry by design of safer chemicals: structure- activity relationships, Drug Metab. Rev., 15, 425-504, 1984.
41. Ashby, J., Styles, J.A., and Paton, D., In vitro evaluation of some derivatives of the carcinogen butter yellow: implications for environmental screening, Br. J. Cancer, 38, 34, 1978.
42. Takihi, N., Rosenkranz, H.S., and Klopman, G., Identification of chemicals for testing in the rodent cancer bioassay, Quality Assurance: Good Practice, Regul., Law, 2, 232-243, 1993.
43. Garner, R.C., Martin, C.N., and Clayson, D.B., Carcinogenic aromatic amines and related compounds, in Chemical Carcinogens, C.E. Searle, Ed., American Chemical Society, Washington, D.C., 1984, 175-276.
44. Ashby, J. and Tennant, R.W., Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP, Mutat. Res., 257, 229-306, 1991.
45. Gold, L.S., Bernstein, L., Magaw, R., and Slone, T.H., Interspecies extrapolation in carcinogenesis: prediction between rats and mice, Environ. Health Pers., 81, 211-219, 1989.
46. Zeiger, E., Genotoxicity database, in Handbook of Carcinogenic Potency and Genotoxicity Databases, L.S. Gold and E. Zeiger, Eds., CRC Press, Boca Raton, FL, 1997, 687-729.
47. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Industrial Chemicals, Vol. 77, World Health Organization, Lyon, France, 2000, 1-563.
48. Bucher, J.R., Shackelford, C.C., Haseman, J.K., Johnson, J.D., Kurtz, P.J., and Persing, R.L., Carcinogenicity studies of oxazepam in mice, Fund. Appl. Toxicol., 23, 280-297, 1994.
49. Bucher, J.R., Haseman, J.K., Herbert, R.A., Hejtmancik, M., and Ryan, M.J., Toxicity and carcinogenicity studies of oxazepam, Toxicol. Sci., 42, 1-12, 1998.
50. NTP, Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-I) in Swiss-Webster and B6C3F1 Mice (Feed Studies), Technical Report Series No. 443, NIH Publication No. 93-3359, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1993.
51. NTP, Draft Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in F344/N Rats (Feed Studies), Technical Report Series No. 468, NIH Publication No. 96-3958, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1996.
52. McGregor, D.B., Chemicals classified by IARC: their potency in tests for carcinogenicity in rodents and their genotoxicity and acute toxicity, IARC Sci Publ., 116, 323-352, 1992.
53. ter Haar, E., Day, B.W., and Rosenkranz, H.S., Direct tubulin polymerization perturbation contributes significantly to the induction of micronuclei in vivo, Mutation Res., 350, 331-337, 1996.
54. Lee, Y., Buchanan, B.G., Klopman, G., Dimayuga, M., and Rosenkranz, H.S., The potential of organ specific toxicity for predicting rodent carcinogenicity, Mutat. Res., 358, 37-62, 1996.
55. MacDonald, J.S., Gerson, R.J., Kornbrust, D.J., Kloss, M.W., Prahalada, S., Berry, P.H., Alberts, A.W., and Bokelman, D.L., Preclinical evaluation of Lovastatin, Am. J. Cardiol., 62, 16J-27J, 1988.
56. Robison, R.L., Suter, W., and Cox, R.H., Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor, Fund. Appl. Toxicol., 23, 9-20, 1994.
57. Levy, R.I., Troendle, A.J., and Fattu, J.M., A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin, Circulation, 87, 45-53, 1993.
58. Tse, F.L.S., Smith, H.T., Ballard, F.H., and Nicoletti, J., Disposition of fluvastatin, an inhibitor of HMG-CoA reductase in mouse, rat, dog and monkey, Biopharm. Drug Dis., 11, 519-531, 1990.
59. Kathawala, F.G., HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia, Med. Res. Rev., 11, 121-146, 1991.
60. Trosko, J.E., Chang, C.C., Upham, B., and Wilson, M., Epigenetic toxicology as toxicant-induced changes in intracellular signaling leading to altered gap junctional intercellular communication, Toxicol. Lett., 102-103, 71-78, 1998.
61. Yamasaki, H., Mesnil, M., Omori, Y., Mironov, N., and Krutovskikh, V., Intercellular communication and carcinogenesis, Mutat. Res., 333, 181-188, 1995.
62. Klaunig, J.E. and Ruch, R.J., Biology of disease: role of inhibition of intercellular communication in carcinogenesis, Lab. Invest., 62, 135-146, 1990.
63. Ames, B.N. and Gold, L.S., Chemical carcinogenesis: too many rodent carcinogens, Proc. Natl. Acad. Sci. USA, 87, 7772-7776, 1990.
64. IARC, Peroxisome Proliferation and Its Role in Carcinogenesis, IARC Tech. Rep. No. 24, International Agency for Research on Cancer, Lyon, France, 1995.
65. Schmid, W., The micronucleus test for cytogenetic analysis, in Chemical Mutagens: Principles and Methods for Their Detection, A. Hollaender, Ed., Plenum Press, New York, 1976, 31-55.
66. Heddle, J.A., Cimino, M.C., Hayashi, M., Romagna, F., Shelby, M.D., Tucker, J.D., Vanparys, P., and MacGregor, J.T., Micronuclei as an index of cytogenetic damage: past, present, and future, Environ. Mol. Mutagen., 18, 277-291, 1991.
67. Mavournin, K.H., Blakey, D.H., Cimino, M.C., Salamone, M.F., and Heddle, J.A., The in vivo micronucleus assay in mammalian bone marrow and peripheral blood, Mutat. Res., 239, 29-80, 1990.
68. Tinwell, H. and Ashby, J., Comparative activity of human carcinogens and NTP rodent carcinogens in the mouse bone marrow micronucleus assay: an integrative approach to genetic toxicity data assessment, Environ. Health Perspect., 102, 758-762, 1994.
69. Tinwell, H. and Ashby, J., Genetic toxicity and potential carcinogenicity of taxol, Carcinogenesis, 15, 1499-1501, 1994.
70. Wilson, L. and Jordan, M.A., Microtubule dynamics: taking aim at a moving target, Chem. Biol., 2, 569-573, 1995.
71. Hamel, E., Antimitotic natural products and their interactions with tubulin, Med. Res. Rev., 16, 207-231, 1996.
72. ter Haar, E., Rosenkranz, H.S., Hamel, E., and Day, B.W., Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents, Bioorganic Med. Chem., 4, 1659-1671, 1996.
73. Pinney, K.G., Bounds, A.D., Dingeman, K.M., Mocharla, V.P., Pettit, G.R., Bai, R., and Hamel, E., A new anti-tubulin agent containing the benzo[b]thiophene ring system, Bioorganic Med. Chem. Lett., 9, 1081-1086, 1999.
74. Grant, S.G., Zhang, Y.P., Klopman, G., and Rosenkranz, H.S., Modeling the mouse lymphoma forward mutational assay: the Gene-Tox program database, Mutat. Res., 465, 201-229, 2000.
75. Rosenkranz, H.S., Structural concepts in the prediction of the toxicity of therapeutical agents, in Burger’s Medicinal Chemistry and Drug Discovery, John Wiley & Sons, New York, 2002.
76. Rosenkranz, H.S., Consideration of structure-activity relationships in toxicology, in Toxicology, H. Marquardt, ed., Academic Press, San Diego, 2002.
77. Pollack, N., Cunningham, A.R., Klopman, G., and Rosenkranz, H.S., Chemical diversity approach for evaluating mechanistic relatedness among toxicological phenomena, SAR QSAR Environ. Res., 10, 533-543, 1999.
78. Rosenkranz, H.S. and Cunningham, A.R., A new approach to evaluate mechanistic relationships among genotoxic phenomena: validation, Mutagenesis, 15, 325-328, 2000.
79. Rosenkranz, H.S. and Cunningham, A.R., Prevalence of mutagens in the environment: experimental data vs. simulations, Mutat. Res., 484, 49-51, 2001.
80. Mersch-Sundermann, V., Schneider, U., Klopman, G., and Rosenkranz, H.S., SOS induction in E. coli and Salmonella mutagenicity: a comparison using 330 compounds, Mutagenesis, 9, 205-224, 1994.
81. Upton, A.C., Clayson, D.G., Jansen, J.D., Rosenkranz, H.S., and Williams, G.M., Report of the International Commission for Protection Against Environmental Mutagens and Carcinogens Task Group on the differentiation between genotoxic and non-genotoxic carcinogens, Mutat. Res., 133, 1-49, 1984.
82. Palajda, M. and Rosenkranz, H.S., Assembly and preliminary analysis of a genotoxicity data base for predicting carcinogens, Mutation Res., 153, 79-134, 1985.
83. Swenberg, J.A., Short, B., Borghoff, S., Strasser, J., and Charbonneau, M., The comparative pathobiology of a2m-globulin nephropathy, Toxicol. Appl. Pharmacol., 97, 35-46, 1989.
84. Rosenkranz, H.S. and Cunningham, A.R., The High Production Volume Chemical Challenge Program: the relevance of the in vivo micronucleus assay, Regul. Toxicol. Pharmacol., 31, 182-189, 2000.
85. Rosenkranz, H.S., Pollack, N., and Cunningham, A.R., Exploring the relationship between inhibition of gap junctional intracellular communication and other biological phenomena, Carcinogenesis, 21, 1007-1011, 2000.
86. Maron, D.M. and Ames, B.N., Revised methods for the Salmonella mutagenicity test, Mutat. Res., 113, 173-215, 1983.
87. Brusick, D., Simmon, V.F., Rosenkranz, H.S., Ray, V., and Stafford, R.S., An evaluation of the E. coli WP2 and WP2uvrA reverse mutation assay, Mutat. Res., 76, 169-190, 1980.
88. Kilbey, B.J., Brusick, D., Bartsch, H., Malling, H.V., Natarajan, A.T., Rosenkranz, H.S., Russell, L.B., Schoneich, J., Vogel, E., Wassom, J.S., Ashby, J., Ehling, U.H., Kada, T., Obe, G., Searle, A.G., and Zimmermann, F.K., Recommendations for development of a genetic screening program, Mutat. Res., 114, 117-177, 1983.
89. Chankong, V., Haimes, Y.Y., Rosenkranz, H.S., and Pet-Edwards, J., The carcinogenicity prediction and battery selection (CPBS) method: a Bayesian approach, Mutat. Res., 153, 135-166, 1985.
90. Cunningham, A.R., Klopman, G., and Rosenkranz, H.S., A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites, Mutat. Res., 349, 85-94, 1996.
91. Rosenkranz, H.S., Zhang, Y.P., and Klopman, G., Risk identification using structural concepts: the potential carcinogenicity of praziquantel, Regul. Toxicol. Pharmacol., 22, 152-161, 1995.
92. Zhang, Y.P., Praagh, A.V., Klopman, G., and Rosenkranz, H.S., Structural basis of the induction of unscheduled DNA synthesis in rat hepatocytes, Mutagenesis, 9, 141-149, 1994.
93. Rosenkranz, M., Rosenkranz, H.S., and Klopman, G., Intercellular communication, tumor promotion and non-genotoxic carcinogenesis: relationships based upon structural considerations, Mutat. Res., 381, 171-188, 1997.
94. Rosenkranz, H.S., Ennever, F.K., Dimayuga, M., and Klopman, G., Significant differences in the structural basis of the induction of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells, Environ. Mol. Mutagen., 16, 149-177, 1990.
95. Yang, W.-L., Klopman, G., and Rosenkranz, H.S., Structural basis of the in vivo induction of micronuclei, Mutat. Res., 272, 111-124, 1992.
96. Rosenkranz, H.S., Matthews, E.J., and Klopman, G., Relationship between cellular toxicity, the maximum tolerated dose, lipophilicity and electrophilicity, Alternative to Laboratory Animals (ATLA), 20, 549-562, 1992.
97. Zhu, X. and Rosenkranz, H.S., Structural basis of the toxicity of chemicals in cultured human HeLa cells, Alternative to Laboratory Animals (ATLA), 28, 557-574, 2000.
98. Rosenkranz, H.S. and Klopman, G., Structural relationships between mutagenicity, maximum tolerated dose, and carcinogenicity in rodents, Environ. Molec. Mutagen., 21, 193-206, 1993.